Latham & Watkins Advises Corvus Pharmaceuticals in its Public Offering of Common Stock

A corporate team advises the clinical-stage biopharmaceutical company in the offering.

February 12, 2021

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, has announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of US$3.50 per share, for gross proceeds of US$30 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Corvus. All of the shares are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represents Corvus Pharmaceuticals on the offering with a corporate deal team led by Bay Area partner Miles Jennings, with associates Michelle Lu and Amanda Dillon. Advice was also provided on tax matters by Los Angeles partner Samuel Weiner, with associate Janet Hsu; and on regulatory matters by Washington, D.C. partner Elizabeth Richards, with associate Chad Jennings.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.